510(k) Report

PMA · Approved

Approved

NMP22 BladderChek Test

P940035PMAApproved Jul 2, 1996603-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Diagnostics Scarborough, Inc. · NAH System, Test, Tumor Marker, For Detection Of Bladder Cancer

Approved on Jul 2, 1996 through premarket approval, which rests on the device’s own clinical evidence after a 603-day review.

Decided
Jul 2, 1996
Review
603 days
Class
Class III
Product code
NAH
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P940035 has 17 supplements since 1997: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

1997: 12000: 12003: 12008: 22011: 12012: 22013: 22015: 12016: 22017: 12018: 12021: 12022: 1
1997high 2 (2008) · low 0 (1998)2022
View FIG. 1 as a table
YearSupplements approved
19971
20001
20031
20082
20111
20122
20132
20151
20162
20171
20181
20211
20221
FIG. 1 — Supplements to P940035, 1997–2022Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NAH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All NAH devices

NAH System, Test, Tumor Marker, For Detection Of Bladder Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · NAH

1in 2022

2008: 22011: 12012: 22013: 22015: 12016: 22017: 22018: 22019: 12021: 12022: 1
2007high 2 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NAH

Too few NAH 510(k)s in any year since 2007 to give a median.

Recalls per year · NAH

No recall names NAH since 2007.

Adverse event reports per year · NAH

1in 2021

2021: 1
2007high 1 (2021) · low 0 (2007)2025

MAUDE reports naming product code NAH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20082—00
20090—00
20100—00
20111—00
20122—00
20132—00
20140—00
20151—00
20162—00
20172—00
20182—00
20191—00
20200—00
20211—01
20221—00
20230—00
20240—00
20250—00
20260—0—
Cite this page

510(k) Report. “P940035: NMP22 BladderChek Test.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P940035

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026